The primary objective ofthe M.D. Anderson Cancer Center CML-P01 is to improve the treatment of patients with chronic myelogenous leukemia. A fundamental component to meeting this objective is the conduct of focused translational research involving human tissue and blood specimens, allowing investigation of the biology of target and normal tissues, evaluation of treatment effects on both target and normal tissue, and modulation of relevant biomarkers. The CML Cell Bank Core will collect, process and maintain human tissue specimens from patients and will disperse these tissues to CML-P01 investigators. The CML Cell Bank Core has the following objectives: 1. Develop and maintain a repository of intact cells, serum, DNA, RNA and protein derived from blood and bone marrow specimens obtained from patients with CML that are receiving care or evaluation at M.D. Anderson Cancer Center. Samples are collected and processed at the time of diagnosis, during therapy with POI associated clinical protocols, while in remission or at relapse. The core will distribute tissue specimens to CML-P01 investigators for analysis and provide expertise in the interpretation of studies performed on tissue sections within CML-P01 projects The Core will provide comprehensive hematopathologic characterization ofthe samples used in CML-P01 projects. 2. Provide stock and customized Reverse Phase Protein Arrays to CML-P01 researchers. 3. Maintain a comprehensive, prospective interactive database with detailed clinical and pathologic data for patients with leukemia and MDS receiving care or evaluation at M.D. Anderson Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-22
Application #
8380204
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
22
Fiscal Year
2012
Total Cost
$134,538
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kanagal-Shamanna, Rashmi; Jain, Preetesh; Takahashi, Koichi et al. (2017) TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123:3717-3724
Jain, Preetesh; Burger, Jan A; Khoury, Joseph D (2017) CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol 92:1113-1114
Zhou, H; Mak, P Y; Mu, H et al. (2017) Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 31:2065-2074
Peters, Haley L; Tripathi, Satyendra C; Kerros, Celine et al. (2017) Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5:319-329
Andersson, B S; Thall, P F; Valdez, B C et al. (2017) Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52:580-587
Issa, Ghayas C; Kantarjian, Hagop M; Gonzalez, Graciela Nogueras et al. (2017) Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130:2084-2091
Jain, Preetesh; Kantarjian, Hagop M; Ghorab, Ahmad et al. (2017) Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123:4391-4402
Raynal, Noël J-M; Da Costa, Elodie M; Lee, Justin T et al. (2017) Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Mol Cancer Ther 16:397-407
Ciurea, Stefan O; Schafer, Jolie R; Bassett, Roland et al. (2017) Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130:1857-1868
Jain, Preetesh; Kantarjian, Hagop; Jain, Nitin et al. (2017) Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol 92:E595-E597

Showing the most recent 10 out of 360 publications